sabato, 3 giugno 2023

Notizie AIOM – anno XVII n. 749

6 Dicembre 2019

FDA Panel to Review Application for Luspatercept in MDS

December 3, 2019 - The FDA’s Oncologic Drugs Advisory Committee (ODAC) has scheduled a hearing for December 18, 2019, to review a supplemental Biologics License Application (sBLA) for luspatercept-aamt for use as a treatment for patients with myelodysplastic syndromes ...
Leggi tutto

6 Dicembre 2019

FDA Grants Abatacept Breakthrough Designation for Acute GVHD

December 4, 2019 - The FDA has granted a breakthrough therapy designation for abatacept for the prevention of moderate-to-severe acute graft-versus-host disease (GVHD) in patients who have undergone hematopoietic stem cell transplants (HSCTs) from unrelated donors. The designation ...
Leggi tutto

6 Dicembre 2019

NICE Approves Palbociclib Combo for HR+ Advanced Breast Cancer

December 2, 2019 - The UK National Institute for Health and Care Excellence (NICE) has approved palbociclib in combination with fulvestrant for the treatment of female patients with hormone receptor (HR)–positive, HER2-negative locally advanced or metastatic breast ...
Leggi tutto